PL2661261T3 - Formulacje immunosupresyjne - Google Patents

Formulacje immunosupresyjne

Info

Publication number: PL2661261T3
Authority: PL; Poland
Prior art keywords: immunosuppressant; formulations; immunosuppressant formulations
Prior art date: 2011-01-07

Application number

PL12700262T

Other languages

English (en)

Inventor

Philippe BOUILLOT

Emeric Reynaud

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-07

Filing date

2012-01-05

Publication date

2020-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44022942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2661261(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-01-05 Application filed by Novartis Ag filed Critical Novartis Ag

2020-01-31 Publication of PL2661261T3 publication Critical patent/PL2661261T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL12700262T 2011-01-07 2012-01-05 Formulacje immunosupresyjne PL2661261T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11150431		2011-01-07
PCT/EP2012/050151 WO2012093161A1 (en)	2011-01-07	2012-01-05	Immunosuppressant formulations
EP12700262.4A EP2661261B1 (en)	2011-01-07	2012-01-05	Immunosuppressant formulations

Publications (1)

Publication Number	Publication Date
PL2661261T3 true PL2661261T3 (pl)	2020-01-31

Family

ID=44022942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12700262T PL2661261T3 (pl)	2011-01-07	2012-01-05	Formulacje immunosupresyjne

Country Status (36)

Country	Link
US (4)	US20130273161A1 (pl)
EP (2)	EP3590507A1 (pl)
JP (2)	JP6111202B2 (pl)
KR (2)	KR101951966B1 (pl)
CN (1)	CN103458877B (pl)
AR (2)	AR084801A1 (pl)
AU (1)	AU2012204835B2 (pl)
BR (1)	BR112013017302B1 (pl)
CA (1)	CA2823616C (pl)
CL (1)	CL2013001979A1 (pl)
CO (1)	CO6761402A2 (pl)
CY (1)	CY1122182T1 (pl)
DK (1)	DK2661261T3 (pl)
EA (1)	EA026144B9 (pl)
EC (1)	ECSP13012812A (pl)
ES (1)	ES2751920T3 (pl)
GT (1)	GT201300178A (pl)
HR (1)	HRP20191842T1 (pl)
HU (1)	HUE045612T2 (pl)
IL (1)	IL227094B (pl)
JO (1)	JO3619B1 (pl)
LT (1)	LT2661261T (pl)
MA (1)	MA34897B1 (pl)
MX (2)	MX371290B (pl)
MY (1)	MY161162A (pl)
PE (1)	PE20140216A1 (pl)
PH (1)	PH12013501442B1 (pl)
PL (1)	PL2661261T3 (pl)
PT (1)	PT2661261T (pl)
SG (1)	SG191286A1 (pl)
SI (1)	SI2661261T1 (pl)
TN (1)	TN2013000257A1 (pl)
TW (2)	TWI610672B (pl)
UA (1)	UA114283C2 (pl)
WO (1)	WO2012093161A1 (pl)
ZA (1)	ZA201304465B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2751920T3 (es)	2011-01-07	2020-04-02	Novartis Ag	Formulaciones inmunosupresoras
HUE054245T2 (hu) *	2014-04-10	2021-08-30	Novartis Ag	Immunszupresszáns formuláció
TW201622721A (zh) *	2014-04-10	2016-07-01	諾華公司	Ｓ１ｐ調節劑之立即釋放劑量療法
US20180042895A1 (en)	2015-02-26	2018-02-15	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
MX378947B (es)	2015-07-03	2025-03-11	Astellas Pharma Inc	Composición farmacéutica estable para administración oral.
US11629124B2 (en)	2017-03-09	2023-04-18	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
KR20200059221A (ko)	2017-09-27	2020-05-28	노파르티스 아게	시포니모드를 포함하는 비경구 제형
MX2020007268A (es)	2017-09-29	2020-08-17	Novartis Ag	Regimen de dosificacion de siponimod.
CA3074416A1 (en)	2017-09-29	2019-04-04	Novartis Ag	Dosing regimen of siponimod
CN109908095A (zh) *	2019-04-08	2019-06-21	肇庆学院	一种西尼莫德片剂及制备方法
WO2021214717A1 (en)	2020-04-23	2021-10-28	Novartis Ag	Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
CN119031939A (zh) *	2022-03-09	2024-11-26	埃斯普投资有限公司	共处理赋形剂组合物
EP4633611A1 (en)	2022-12-12	2025-10-22	Synthon B.V.	Pharmaceutical composition of siponimod

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3872113A (en)	1972-05-30	1975-03-18	Endo Lab	Hydroxy- and acetoxy-phthalaldehydric acid, O-(substituted) oximes
DE69321823T2 (de)	1992-10-21	1999-06-02	Taito Co., Ltd., Tokio/Tokyo	2-amino-1, 3- propandiolverbindung und immunosuppressium
HU225964B1 (en)	1994-07-12	2008-01-28	Berwind Pharma Service	Moisture barrier film coating composition, method, and coated form
ES2230571T3 (es)	1995-12-28	2005-05-01	Mitsubishi Pharma Corporation	`composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
MY121470A (en)	1999-05-03	2006-01-28	Ranbaxy Lab Ltd	Stable solid pharmaceutical compositions containing enalapril maleate
WO2002018395A1 (en)	2000-08-31	2002-03-07	Merck & Co., Inc.	Phosphate derivatives as immunoregulatory agents
AR041786A1 (es)	2002-03-15	2005-06-01	Novartis Ag	Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
CA2483594C (en)	2002-05-16	2011-02-15	Novartis Ag	Use of edg receptor binding agents in cancer
KR20050055050A (ko) *	2002-11-07	2005-06-10	니폰 제톡 가부시키가이샤	구강용 조성물 기제 및 구강용 조성물
PE20130200A1 (es)	2003-04-08	2013-03-09	Novartis Ag	Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
WO2004113330A1 (en)	2003-05-19	2004-12-29	Irm Llc	Immunosuppressant compounds and compositions
MY150088A (en)	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
MXPA05012461A (es)	2003-05-19	2006-02-22	Irm Llc	Compuestos y composiciones inmunosupresores.
US20050090520A1 (en)	2003-09-12	2005-04-28	Per Lindquist	Treatment of disease or injury of the nervous system with FTY720
CN102335116A (zh)	2003-10-29	2012-02-01	惠氏有限责任公司	包含aplindore和其衍生物的缓释药物组合物
JP2007536310A (ja)	2004-05-03	2007-12-13	ノバルティスアクチエンゲゼルシャフト	Ｓ１ｐ受容体アゴニストおよびｊａｋ３キナーゼ阻害剤を含む、組合せ剤
US20060002999A1 (en)	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
NZ554720A (en)	2004-11-29	2011-04-29	Novartis Ag	Compositions and uses of fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol)
EP1688141A1 (en)	2005-01-31	2006-08-09	elbion AG	The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
GB0504544D0 (en)	2005-03-04	2005-04-13	Novartis Ag	Organic compounds
RU2296999C2 (ru)	2005-03-09	2007-04-10	Алексей Арнольдович Корженевский	Способ выявления критериев для проведения адекватной иммунотерапии гнойно-септических заболеваний
GT200600350A (es)	2005-08-09	2007-03-28		Formulaciones líquidas
ES2620293T3 (es)	2005-09-09	2017-06-28	Paladin Labs Inc.	Composición de liberación sostenida de fármacos
GB0612721D0 (en)	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
WO2008072056A1 (en)	2006-12-14	2008-06-19	Pfizer Limited	Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (de)	2007-04-23	2008-11-13	Grünenthal GmbH	Tapentadol zur Schmerzbehandlung bei Arthrose
US20100093672A1 (en)	2007-05-04	2010-04-15	Yves-Alain Barde	Use of s1p receptor modulator
ES2545361T3 (es) *	2007-10-12	2015-09-10	Novartis Ag	Composiciones que comprenden moduladores del receptor de esfingosina 1-fosfato (S1P)
HRP20170246T4 (hr)	2008-03-17	2020-02-07	Actelion Pharmaceuticals Ltd.	Režim doziranja za selektivni agonist s1p1-receptora
CA2728514C (en)	2008-06-20	2020-08-11	Novartis Ag	Paediatric compositions for treating multiple sclerosis
AU2009273259B2 (en)	2008-07-23	2013-05-02	Novartis Ag	Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
MX2011001832A (es)	2008-08-18	2011-04-28	Novartis Ag	Compuestos para el tratamiento de neuropatias perifericas.
RS53041B (sr) *	2008-12-18	2014-04-30	Novartis Ag	Hemifumaratna so 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
CN103204794A (zh)	2008-12-18	2013-07-17	诺瓦提斯公司	新的盐
ES2531831T3 (es)	2008-12-18	2015-03-20	Novartis Ag	Forma polimórfica del ácido 1-(4-{1-[(E)-4-ciclohexil-3-trifluorometil-benciloxiimino]-etil}-2-etil-bencil)-azetidin-3-carboxilico
CA2746859A1 (en)	2008-12-19	2010-06-24	Novartis Ag	Mouthpiece for an inhaler
JP5657565B2 (ja)	2008-12-22	2015-01-21	ノバルティスアーゲー	Ｓ１ｐ受容体アゴニストの投与レジメン
PT4098256T (pt)	2008-12-22	2025-04-10	Novartis Ag	Regime de dosagem para um agonista do recetor de s1p
SG10201406168RA (en)	2009-09-29	2014-11-27	Novartis Ag	Dosage regimen of an s1p receptor modulator
ES2751920T3 (es)	2011-01-07	2020-04-02	Novartis Ag	Formulaciones inmunosupresoras
WO2012095853A1 (en)	2011-01-10	2012-07-19	Novartis Pharma Ag	Modified release formulations comprising sip receptor modulators
TW201320994A (zh)	2011-10-11	2013-06-01	Novartis Ag	投藥療程
SG11201506493VA (en)	2013-04-04	2015-10-29	Novartis Ag	Identifying patient response to s1p receptor modulator administration
HUE054245T2 (hu)	2014-04-10	2021-08-30	Novartis Ag	Immunszupresszáns formuláció

2012
- 2012-01-05 ES ES12700262T patent/ES2751920T3/es active Active
- 2012-01-05 HU HUE12700262A patent/HUE045612T2/hu unknown
- 2012-01-05 SI SI201231683T patent/SI2661261T1/sl unknown
- 2012-01-05 PE PE2013001522A patent/PE20140216A1/es active IP Right Grant
- 2012-01-05 BR BR112013017302-5A patent/BR112013017302B1/pt active IP Right Grant
- 2012-01-05 HR HRP20191842TT patent/HRP20191842T1/hr unknown
- 2012-01-05 KR KR1020137020755A patent/KR101951966B1/ko not_active Expired - Fee Related
- 2012-01-05 PL PL12700262T patent/PL2661261T3/pl unknown
- 2012-01-05 EP EP19188018.6A patent/EP3590507A1/en active Pending
- 2012-01-05 PT PT127002624T patent/PT2661261T/pt unknown
- 2012-01-05 UA UAA201307576A patent/UA114283C2/uk unknown
- 2012-01-05 MX MX2017007300A patent/MX371290B/es unknown
- 2012-01-05 EP EP12700262.4A patent/EP2661261B1/en active Active
- 2012-01-05 SG SG2013047923A patent/SG191286A1/en unknown
- 2012-01-05 MA MA36170A patent/MA34897B1/fr unknown
- 2012-01-05 KR KR1020197004860A patent/KR102166885B1/ko not_active Expired - Fee Related
- 2012-01-05 CA CA2823616A patent/CA2823616C/en active Active
- 2012-01-05 AU AU2012204835A patent/AU2012204835B2/en active Active
- 2012-01-05 LT LT12700262T patent/LT2661261T/lt unknown
- 2012-01-05 CN CN201280004869.2A patent/CN103458877B/zh active Active
- 2012-01-05 JP JP2013547861A patent/JP6111202B2/ja active Active
- 2012-01-05 EA EA201391018A patent/EA026144B9/ru active Protection Beyond IP Right Term
- 2012-01-05 DK DK12700262.4T patent/DK2661261T3/da active
- 2012-01-05 JO JOP/2012/0005A patent/JO3619B1/ar active
- 2012-01-05 WO PCT/EP2012/050151 patent/WO2012093161A1/en not_active Ceased
- 2012-01-05 MX MX2013007909A patent/MX357304B/es active IP Right Grant
- 2012-01-05 PH PH1/2013/501442A patent/PH12013501442B1/en unknown
- 2012-01-06 TW TW101100702A patent/TWI610672B/zh active
- 2012-01-06 AR ARP120100047A patent/AR084801A1/es not_active Application Discontinuation
- 2012-01-06 TW TW104142389A patent/TWI583380B/zh active
- 2012-01-06 MY MYPI2013002251A patent/MY161162A/en unknown
2013
- 2013-06-14 TN TNP2013000257A patent/TN2013000257A1/fr unknown
- 2013-06-14 US US13/917,730 patent/US20130273161A1/en not_active Abandoned
- 2013-06-18 ZA ZA2013/04465A patent/ZA201304465B/en unknown
- 2013-06-20 IL IL227094A patent/IL227094B/en active IP Right Grant
- 2013-07-05 CL CL2013001979A patent/CL2013001979A1/es unknown
- 2013-07-05 GT GT201300178A patent/GT201300178A/es unknown
- 2013-07-16 CO CO13168667A patent/CO6761402A2/es unknown
- 2013-08-07 EC ECSP13012812 patent/ECSP13012812A/es unknown
2017
- 2017-03-13 JP JP2017047220A patent/JP6324569B2/ja active Active
2019
- 2019-10-22 CY CY20191101097T patent/CY1122182T1/el unknown
2020
- 2020-02-28 US US16/804,926 patent/US20200199069A1/en not_active Abandoned
2021
- 2021-04-14 US US17/230,175 patent/US12071402B2/en active Active
2022
- 2022-01-17 AR ARP220100086A patent/AR124662A2/es unknown
2024
- 2024-08-13 US US18/802,089 patent/US20250084034A1/en active Pending

Also Published As

Publication number	Publication date
TN2013000257A1 (en)	2014-11-10
CO6761402A2 (es)	2013-09-30
CN103458877A (zh)	2013-12-18
EA201391018A1 (ru)	2013-11-29
EP2661261A1 (en)	2013-11-13
US12071402B2 (en)	2024-08-27
NZ612420A (en)	2015-05-29
CL2013001979A1 (es)	2013-11-22
CY1122182T1 (el)	2020-11-25
UA114283C2 (uk)	2017-05-25
CA2823616A1 (en)	2012-07-12
SI2661261T1 (sl)	2019-11-29
JP2014501770A (ja)	2014-01-23
MX371290B (es)	2020-01-24
TW201609092A (zh)	2016-03-16
LT2661261T (lt)	2019-10-25
US20220064110A1 (en)	2022-03-03
PT2661261T (pt)	2019-10-25
IL227094B (en)	2019-03-31
US20200199069A1 (en)	2020-06-25
EP2661261B1 (en)	2019-07-31
HUE045612T2 (hu)	2020-01-28
MY161162A (en)	2017-04-14
PE20140216A1 (es)	2014-03-01
KR20190025727A (ko)	2019-03-11
MA34897B1 (fr)	2014-02-01
US20130273161A1 (en)	2013-10-17
KR20140037815A (ko)	2014-03-27
SG191286A1 (en)	2013-07-31
TWI583380B (zh)	2017-05-21
PH12013501442B1 (en)	2018-04-20
JO3619B1 (ar)	2020-08-27
GT201300178A (es)	2014-12-30
CN103458877B (zh)	2016-06-08
AU2012204835B2 (en)	2015-07-09
BR112013017302A2 (pt)	2016-10-25
ECSP13012812A (es)	2013-09-30
DK2661261T3 (da)	2019-10-21
EA026144B1 (ru)	2017-03-31
MX357304B (es)	2018-07-04
EA026144B9 (ru)	2021-10-26
EP3590507A1 (en)	2020-01-08
AR124662A2 (es)	2023-04-19
JP2017141248A (ja)	2017-08-17
TWI610672B (zh)	2018-01-11
JP6324569B2 (ja)	2018-05-16
AR084801A1 (es)	2013-06-26
AU2012204835A1 (en)	2013-08-01
BR112013017302B1 (pt)	2021-12-07
HRP20191842T1 (hr)	2019-12-27
ZA201304465B (en)	2014-02-26
ES2751920T3 (es)	2020-04-02
US20250084034A1 (en)	2025-03-13
TW201249438A (en)	2012-12-16
KR101951966B1 (ko)	2019-02-25
KR102166885B1 (ko)	2020-10-19
MX2013007909A (es)	2013-08-29
PH12013501442A1 (en)	2013-09-09
JP6111202B2 (ja)	2017-04-05
CA2823616C (en)	2019-01-29
WO2012093161A1 (en)	2012-07-12

Publication	Publication Date	Title
IL227094B (en)	2019-03-31	Immunosuppressive preparations
EP2701734A4 (en)	2016-11-23	LIPOSOMAL FORMULATIONS
GB201111438D0 (en)	2011-08-17	Formulation
IL232305A0 (en)	2014-06-30	pharmaceutical preparations
ZA201309221B (en)	2014-08-27	Formulation
ZA201306016B (en)	2014-04-30	Bendamustine formulations
IL229700A0 (en)	2014-01-30	Dronvir formulations
GB201114725D0 (en)	2011-10-12	Ophthalmic formulations
ZA201402456B (en)	2015-03-25	Formulation
EP2765992A4 (en)	2015-04-08	FOAM FORMULATIONS
GB201110278D0 (en)	2011-08-03	Formulations
EP2782585A4 (en)	2015-08-05	ANTIVIRAL PREPARATIONS
GB201106958D0 (en)	2011-06-08	Formulation
GB201107626D0 (en)	2011-06-22	Formulations
GB201111578D0 (en)	2011-08-24	Pharmeutical formulations
GB201111013D0 (en)	2011-08-10	Formulations
GB201107627D0 (en)	2011-06-22	Formulations
GB201105410D0 (en)	2011-05-11	Formulations
GB201104049D0 (en)	2011-04-20	Formulations
GB201104048D0 (en)	2011-04-20	Formulations
GB201102795D0 (en)	2011-03-30	Formulations
GB201105360D0 (en)	2011-05-11	Formulations
GB201104284D0 (en)	2011-04-27	Formulation
GB201103767D0 (en)	2011-04-20	Cosmetic formulations
GB201103769D0 (en)	2011-04-20	Cosmetic formulations